Ibrutinib
Autoimmune Cytopenia Associated With Chronic Lymphocytic Leukemia
Institut Paoli-CalmettesSmall moleculeDormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Autoimmune Cytopenia Associated With Chronic Lymphocytic Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Idelalisib Institut Paoli-Calmettes | D |
Same molecule, other indications
Ibrutinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →